Jugmohit S Toor
Overview
Explore the profile of Jugmohit S Toor including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
197
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McShan A, Flores-Solis D, Sun Y, Garfinkle S, Toor J, Young M, et al.
Nat Commun
. 2023 Dec;
14(1):8204.
PMID: 38081856
The conformational landscapes of peptide/human leucocyte antigen (pHLA) protein complexes encompassing tumor neoantigens provide a rationale for target selection towards autologous T cell, vaccine, and antibody-based therapeutic modalities. Here, using...
2.
Yarmarkovich M, Marshall Q, Warrington J, Premaratne R, Farrel A, Groff D, et al.
Nature
. 2023 Nov;
623(7988):872.
PMID: 37938785
No abstract available.
3.
Yarmarkovich M, Marshall Q, Warrington J, Premaratne R, Farrel A, Groff D, et al.
Nature
. 2023 Nov;
623(7988):820-827.
PMID: 37938771
The majority of oncogenic drivers are intracellular proteins, constraining their immunotherapeutic targeting to mutated peptides (neoantigens) presented by individual human leukocyte antigen (HLA) allotypes. However, most cancers have a modest...
4.
Liu T, Toor J, Subedi K, Wang J, Yi Q, Loveless I, et al.
Cell Mol Immunol
. 2022 Sep;
19(11):1314-1316.
PMID: 36068293
No abstract available.
5.
Yarmarkovich M, Marshall Q, Warrington J, Premaratne R, Farrel A, Groff D, et al.
Nature
. 2021 Nov;
599(7885):477-484.
PMID: 34732890
The majority of oncogenic drivers are intracellular proteins, thus constraining their immunotherapeutic targeting to mutated peptides (neoantigens) presented by individual human leukocyte antigen (HLA) allotypes. However, most cancers have a...
6.
Overall S, Toor J, Hao S, Yarmarkovich M, ORourke S, Morozov G, et al.
Nat Commun
. 2020 Apr;
11(1):1909.
PMID: 32312993
Peptide exchange technologies are essential for the generation of pMHC-multimer libraries used to probe diverse, polyclonal TCR repertoires in various settings. Here, using the molecular chaperone TAPBPR, we develop a...
7.
McShan A, Devlin C, Overall S, Park J, Toor J, Moschidi D, et al.
Proc Natl Acad Sci U S A
. 2019 Dec;
116(51):25602-25613.
PMID: 31796585
The interplay between a highly polymorphic set of MHC-I alleles and molecular chaperones shapes the repertoire of peptide antigens displayed on the cell surface for T cell surveillance. Here, we...
8.
McShan A, Natarajan K, Kumirov V, Flores-Solis D, Jiang J, Badstubner M, et al.
Nat Chem Biol
. 2018 Jul;
14(8):811-820.
PMID: 29988068
Chaperones TAPBPR and tapasin associate with class I major histocompatibility complexes (MHC-I) to promote optimization (editing) of peptide cargo. Here, we use solution NMR to investigate the mechanism of peptide...
9.
Toor J, Rao A, McShan A, Yarmarkovich M, Nerli S, Yamaguchi K, et al.
Front Immunol
. 2018 Feb;
9:99.
PMID: 29441070
The identification of recurrent human leukocyte antigen (HLA) neoepitopes driving T cell responses against tumors poses a significant bottleneck in the development of approaches for precision cancer therapeutics. Here, we...